trending Market Intelligence /marketintelligence/en/news-insights/trending/djNTfeAFY9KGEwRN2P-P2A2 content esgSubNav
In This List

Humana to cover NanoString's breast cancer testing kit

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Humana to cover NanoString's breast cancer testing kit

Humana Inc. decided to include NanoString Technologies Inc.'s Prosigna breast cancer gene signature assay in its coverage.

The insurer's decision is in accordance with the ASCO guidelines, which consider Prosigna to be medically necessary in assessing whether adjuvant chemotherapy in ER-positive, HER2-negative, node-negative breast cancer patients is required, when adjuvant chemotherapy is not precluded due to any other factor.